Seer IncSEER
SEER
About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Employees: 134
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
4.51% less ownership
Funds ownership: 53.92% [Q4 2024] → 49.41% (-4.51%) [Q1 2025]
6% less funds holding
Funds holding: 71 [Q4 2024] → 67 (-4) [Q1 2025]
32% less capital invested
Capital invested by funds: $68.4M [Q4 2024] → $46.6M (-$21.8M) [Q1 2025]
45% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 29
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
Research analyst outlook
We haven’t received any recent analyst ratings for SEER.
Financial journalist opinion
Based on 3 articles about SEER published over the past 30 days
Positive
Zacks Investment Research
5 days ago
What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?
Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
2 weeks ago
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics
Neutral
GlobeNewsWire
2 weeks ago
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics.
Neutral
Seeking Alpha
1 month ago
Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnings conference call.
Negative
Zacks Investment Research
1 month ago
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.32 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 37%, driven by increased product sales and service revenue Revenue grew 37%, driven by increased product sales and service revenue
Neutral
GlobeNewsWire
1 month ago
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025.
Negative
Zacks Investment Research
2 months ago
After Plunging -16.59% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Zacks Investment Research
2 months ago
After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
3 months ago
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™